Psoriasis

Zasocitinib met all primary and secondary end points, showing rapid PASI 75 responses and high rates of skin clearance vs placebo and apremilast.

The ustekinumab biosimilar DMB-3115 matched reference therapy in efficacy and safety for moderate to severe plaque psoriasis, according to a phase 3 trial.

A large review identifies 70 safety signals for bimekizumab, confirming known risks while revealing previously unreported adverse events.

Adalimumab significantly reduces activity limitations and boosts work ability and quality of life in patients with psoriasis.

Exposure to antibiotics is linked to higher risk of biologic discontinuation in psoriasis, potentially through gut microbiota changes.

Guselkumab significantly inhibited structural joint damage and improved symptoms in active PsA through 48 weeks.

New findings reveal high rates of depression, anxiety, and sleep issues in individuals with psoriatic arthritis and palmoplantar psoriasis.

Tildrakizumab maintained a favorable safety profile through 208 weeks in patients with psoriatic arthritis, with no new safety signals reported.

More than 50% of patients with psoriasis are eligible for systemic treatment, and nearly 90% would switch to an effective oral therapy with a favorable safety profile.

Higher body size and metabolic factors are linked to worse psoriasis and lower biologic treatment success.

A 16-week Mediterranean diet reduced psoriasis severity and improved metabolic health in patients with mild to moderate psoriasis.

Guselkumab becomes the first interleukin-23 inhibitor approved for children with plaque psoriasis or active psoriatic arthritis.

A new study highlights the epidemiological, humanistic, and economic impact of pediatric psoriasis, with findings showing greater challenges in moderate to severe cases.

A study explores how people with psoriasis use digital media, revealing benefits, pitfalls, and gaps in physician-patient communication.

A study reveals high drug survival rates for anti-TNF biosimilars in treating psoriasis and psoriatic arthritis, highlighting their long-term efficacy and safety.

A large cohort study finds elevated risks of sepsis, genitourinary infections, and longer hospital stays in patients with hidradenitis suppurativa (HS).

SB17, a new ustekinumab biosimilar, demonstrates comparable efficacy and safety for psoriasis and psoriatic arthritis, enhancing patient experience and convenience.

National Psoriasis Awareness Month offers an opportunity to examine how advances in systemic therapy, combined with patient-centered care models, are reshaping the treatment landscape.

Long-term exposure to pollutants was linked to higher psoriasis risk, especially in people with genetic predispositions.

A multicenter study finds no difference in outcomes between frail and nonfrail elderly patients treated with tildrakizumab over 2 years.

Interclass biologic switching can improve outcomes, but it also increases infection rates.

Clearer information on fertility, heredity, and medication use is necessary during family planning for patients with psoriasis.

In an extension trial, apremilast showed sustained clinical benefit and a consistent safety profile in children and adolescents with moderate to severe plaque psoriasis.

New research identifies diabetes as an independent predictor of major adverse cardiovascular events in patients with both psoriasis and coronary artery disease.

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals with diverse skin tones.

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council guidelines.

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.

Target trial emulation study finds no added effectiveness or persistence with combination therapy for plaque psoriasis.

Patients with low psoriasis body surface area (BSA) can have similar quality of life impacts and symptom burdens as those with higher BSA, a new study finds.

US claims data show patients with generalized pustular psoriasis (GPP) face up to a 4-fold higher mortality risk compared with the general population.